Title:Therapeutic Interventions of Tissue Specific Autoimmune Onset in Systemic Lupus Erythematosus
Volume: 17
Issue: 15
Author(s): Subhajit Dasgupta*Shaoni Dasgupta
Affiliation:
- Microbiology, Immunology and Biochemistry, Albert Lake Drive, The Quarter, A-I-2640, P.O. Box 318; Anguilla,United Kingdom
Keywords:
Autoimmune disease, B cell, ER-alpha, Lupus, monoclonal antibody, NF-kappa-B.
Abstract: Background: Systemic lupus erythematosus (lupus) is a female predominant autoimmune
disease. The autoreactive B cells and T helper cells together are known to develop adverse immune responses
in different tissues like kidney, bone, cardiovascular and central nervous system. Progression
of disease is associated with deposition of immune complex which initiates tissue damage. The therapy
for lupus still includes corticosteroids to reduce allergic manifestations and inflammatory immune responses.
Recent observations suggested that, mycophenolate mofetil and cyclophosphamide treatment
in combination with corticosteroids have benefit in lupus therapy.
Method: The prospect of B cell depletion by CD20 targeted monoclonal antibody Rituximab has been
demonstrated in lupus patients. The CD52 specific monoclonal antibody Alemtuzumab is another
proposition for lupus therapy. The drug Belimumab inhibits B cell activation by altering BAFF/APRIL
signal cascade. Recent discovery of the CD22 targeted Epratuzumab also shows therapeutic prospect.
The researches on new generation drugs for autoimmune lupus include search for inhibitors of CD40-
CD40Ligand interactions, CD86 activation, selective modulation of complement cascades. The choice
of inhibitors of transcription factor NF-κBp65 and selective modulators for estrogen receptor alpha are
proposed areas of lupus drug discovery research.
Results & Conclusion: Keeping a close eye on the mechanisms of disease onset, a comprehensive
view is provided on recent therapy of systemic lupus erythematosus.
